trending Market Intelligence /marketintelligence/en/news-insights/trending/linHFqeP7hbkCyroDDFPsw2 content esgSubNav
In This List

Astellas Pharma to transfer pain drug rights to Grünenthal

Blog

Insight Weekly: Unease roils markets; US likely to slip into recession; firms' cash ratios fall

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch


Astellas Pharma to transfer pain drug rights to Grünenthal

Astellas Pharma Inc. said Astellas Pharma Europe Ltd. signed a definitive agreement with Grünenthal to transfer the rights for Astella's Qutenza, a pain relief patch, in Europe, the Middle East and Africa to Grünenthal.

The deal is expected to be completed in 2018.

Tokyo-based Astella's Qutenza is used for the treatment of peripheral neuropathic pain in adults.